Seeking vancomycin resistant Staphylococcus aureus among patients with vancomycin-resistant enterococci

被引:25
作者
Franchi, D
Climo, MW
Wong, AHM
Edmond, MB
Wenzel, RP
机构
[1] Virginia Commonwealth Univ, Med Coll Virginia, Div Qual Hlth Care, Richmond, VA 23298 USA
[2] Virginia Commonwealth Univ, Med Coll Virginia, Dept Internal Med, Richmond, VA 23298 USA
关键词
D O I
10.1086/313530
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Clinical isolates of Staphylococcus aureus displaying intermediate resistance to vancomycin (VISA) have been identified. The objective of our study was to identify VISA colonization among patients known to be colonized or infected with vancomycin-resistant: enterococci (VRE). Eight weekly point prevalence screening surveys for VRE and S. aureus were conducted on 5 hospital units. Of the 243 patients screened, 31 (12.8%) were colonized with VRE. In addition, 18 inpatients were already known to be VRE-positive. Fourteen (28.6%) of the 49 VRE-positive patients were co-colonized with S. aureus. All 30 S. aureus isolates from these 14 patients were methicillin-resistant (MRSA) but remained vancomycin-susceptible (minimal inhibitory concentration [MIC] range, 0.75-2 mu g/mL). Population analysis profiling demonstrated no evidence of heteroresistant subpopulations that could grow on agar containing 3 mu g/mL, vancomycin for any of the MRSA isolates. Although 23 (77%) of 30 staphylococcal isolates had vancomycin MICs of 1.5 or 2 mu g/mL, no VISA strains (MICs, 8-16 mu g/mL) were recovered.
引用
收藏
页码:1566 / 1568
页数:3
相关论文
共 13 条
  • [1] [Anonymous], MORB MORTAL WKLY REP
  • [2] Centers for Disease Control and Prevention (CDC), 1997, MMWR Morb Mortal Wkly Rep, V46, P813
  • [3] Combinations of vancomycin and β-lactams are synergistic against staphylococci with reduced susceptibilities to vancomycin
    Climo, MW
    Patron, RL
    Archer, GL
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1999, 43 (07) : 1747 - 1753
  • [4] RECOVERY OF RESISTANT ENTEROCOCCI DURING VANCOMYCIN PROPHYLAXIS
    KAPLAN, AH
    GILLIGAN, PH
    FACKLAM, RR
    [J]. JOURNAL OF CLINICAL MICROBIOLOGY, 1988, 26 (06) : 1216 - 1218
  • [5] National Committee for Clinical Laboratory Standards, 1997, M7A4 NCCLS
  • [6] NOBLE WC, 1992, FEMS MICROBIOL LETT, V93, P195
  • [7] First clinical isolate of vancomycin-intermediate Staphylococcus aureus in a French hospital
    Ploy, MC
    Grélaud, C
    Martin, C
    de Lumley, L
    Denis, F
    [J]. LANCET, 1998, 351 (9110) : 1212 - 1212
  • [8] Staphylococcus aureus with reduced susceptibility to vancomycin isolated from a patient with fatal bacteremia
    Rotun, SS
    McMath, V
    Schoonmaker, DJ
    Maupin, PS
    Tenover, FC
    Hill, BC
    Ackman, DM
    [J]. EMERGING INFECTIOUS DISEASES, 1999, 5 (01) : 147 - 149
  • [9] Inhibition of cell wall turnover and autolysis by vancomycin in a highly vancomycin-resistant mutant of Staphylococcus aureus
    Sieradzki, K
    Tomasz, A
    [J]. JOURNAL OF BACTERIOLOGY, 1997, 179 (08) : 2557 - 2566
  • [10] The development of vancomycin resistance in a patient with methicillin-resistant Staphylococcus aureus infection
    Sieradzki, K
    Roberts, RB
    Haber, SW
    Tomasz, A
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1999, 340 (07) : 517 - 523